Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma

被引：3
|
作者：
Fenk, R
Hoyer, B
Steidl, U
Kondakci, M
Graef, T
Heuk, R
Ruf, L
Strupp, C
Neumann, F
Rohr, UP
Hildebrandt, B
Haas, R
Kobbe, G
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany
[2] Harvard Univ, Inst Med, Div Hematol Oncol, Boston, MA 02115 USA
[3] Univ Dusseldorf, Dept Human Genet & Anthropol, D-40225 Dusseldorf, Germany
来源：
LEUKEMIA | 2005年 / 19卷 / 01期
关键词：
D O I：
10.1038/sj.leu.2403564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：156 / 159
页数：5
相关论文
共 50 条
  • [21] High-dose chemotherapy in multiple myeloma - Reply
    Attal, M
    Harousseau, JL
    Bataille, R
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (24): : 1845 - 1845
  • [22] High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
    Ychou, M
    Raoul, JL
    Desseigne, F
    Borel, C
    Caroli-Bosc, FX
    Jacob, JH
    Seitz, JF
    Kramar, A
    Hua, A
    Lefebvre, P
    Couteau, C
    Merrouche, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (05) : 383 - 391
  • [23] HIGH-DOSE ETOPOSIDE AS SINGLE-AGENT CHEMOTHERAPY FOR SMALL CELL-CARCINOMA OF THE LUNG
    WOLFF, SN
    JOHNSON, DH
    HANDE, KR
    HAINSWORTH, JD
    GRECO, FA
    CANCER TREATMENT REPORTS, 1983, 67 (10): : 957 - 958
  • [24] High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
    M. Ychou
    J. Raoul
    F. Desseigne
    C. Borel
    F. Caroli-Bosc
    J. Jacob
    J. Seitz
    A. Kramar
    A. Hua
    P. Lefebvre
    C. Couteau
    Y. Merrouche
    Cancer Chemotherapy and Pharmacology, 2002, 50 : 383 - 391
  • [25] In vitro dendritic cell generation and lymphocyte subsets in myeloma patients:: influence of thalidomide and high-dose chemotherapy treatment
    Schütt, P
    Buttkereit, U
    Brandhorst, D
    Lindemann, M
    Schmiedl, S
    Grosse-Wilde, H
    Seeber, S
    Nowrousian, MR
    Opalka, B
    Moritz, T
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (05) : 506 - 512
  • [26] THE ROLE OF THALIDOMIDE MAINTENANCE FOLLOWING HIGH DOSE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA
    Bila, J.
    Lekovic, D.
    Smiljanic, M.
    Sretenovic, A.
    Vujic, D.
    Veljkovic, D.
    Antic, D.
    Sefer, D.
    Kraguljac, N.
    Andjelic, B.
    Todorovic, M.
    Elezovic, I.
    Tomin, D.
    Gotic, M.
    Mihaljevic, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 391 - 392
  • [27] Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma: a systematic review
    Harrison, SJ
    Prince, M
    Adena, M
    Smith, DK
    Hertel, J
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 104 - 105
  • [28] High-dose treatment of multiple myeloma
    Gahrton, G
    Björkstrand, B
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 30 (02) : 173 - 180
  • [29] In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment
    Philipp Schütt
    Ulrike Buttkereit
    Dieter Brandhorst
    Monika Lindemann
    Sven Schmiedl
    Hans Grosse-Wilde
    Siegfried Seeber
    Mohammad Resa Nowrousian
    Bertram Opalka
    Thomas Moritz
    Cancer Immunology, Immunotherapy, 2005, 54 : 506 - 512
  • [30] High-dose sequential chemotherapy in the treatment of myeloma
    Canales, M
    Ojeda, E
    Alvárez, MT
    Jiménez, V
    Jiménez, MT
    Hernández, D
    Aguado, MJ
    Bustos, JG
    Hernández-Navarro, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 352 - 352
12345